1. Home
  2. RPD vs RGNX Comparison

RPD vs RGNX Comparison

Compare RPD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rapid7 Inc.

RPD

Rapid7 Inc.

N/A

Current Price

$12.14

Market Cap

746.5M

Sector

Technology

ML Signal

N/A

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

N/A

Current Price

$7.43

Market Cap

793.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RPD
RGNX
Founded
2000
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
746.5M
793.5M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
RPD
RGNX
Price
$12.14
$7.43
Analyst Decision
Hold
Buy
Analyst Count
25
11
Target Price
$11.71
★ $23.73
AVG Volume (30 Days)
★ 1.6M
1.0M
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 18.08
EPS
★ 0.11
N/A
Revenue
★ $685,083,000.00
$10,393,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$29.31
P/E Ratio
$108.00
★ N/A
Revenue Growth
N/A
★ 126.48
52 Week Low
$4.97
$5.46
52 Week High
$19.84
$16.19

Technical Indicators

Market Signals
Indicator
RPD
RGNX
Relative Strength Index (RSI) 52.42 38.23
Support Level $12.24 $7.12
Resistance Level $13.44 $11.43
Average True Range (ATR) 0.92 0.44
MACD -0.03 0.02
Stochastic Oscillator 62.36 29.14

Price Performance

Historical Comparison
RPD
RGNX

About RPD Rapid7 Inc.

Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Share on Social Networks: